BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

06269455 Supplier Number: 53 8756 (USE FORMAT 7 FOR FULLTEXT)
New industry trends are reviving interest in this natural ingredient.
April, 1999
Word Count: 1484

... Shea butter has always been used as a staple of African pharmacology. It acts as an effective decongestant, for example. Used for its draining and anti-*inflammatory* properties, as soothing in sprains and strains, and
is a widely used ointment for hemorrhoids and burns. This wonderful healing agent is also used for [illegible].

...Shea fruit is harvested [illegible] butter is made in an African village.
Botanical Aspects
A hardy tree native to the [illegible] the Shea tree (*Butyrospermum* *parkii* Kotsch) grows [illegible] to 50 ft high. It usually lives for a couple of centuries, developing vast foliage. The dark green foliage is...hour and persists for eight hours [illegible] subjects, a daily application maintains a very good moisturization of the superficial layers of the skin.
Anti-*inflammatory* properties
Shea butter is traditionally used for alleviating rheumatism, which suggests an anti-*inflammatory* activity. This has been substantiated (Tella) in a study of several [illegible] gestion. Shea butter is tested on 33 volunteers against [illegible] containing...

...Pharmacopoeia), a [illegible] tract.
Nasal congestion is caused by [illegible] that can be relieved by two mechanisms: a vasoconstrictor [illegible] anti-*inflammatory*. Only the second mechanism applies for Shea [illegible] has never demonstrated any vasoconstricting activity.
Efficient Release of [illegible] ingredients
This study (K[illegible]

2/6,K/2 (Item 2 from file: 16)

04595691 Supplier [illegible] (USE FORMAT 7 FOR FULLTEXT)
Protecting skin and [illegible]
Oct, 1996
Word Count: 1592

... is conce[illegible] the [illegible] age users to stay in the sun longer, increasing exposure to radiation and also increasing the risk of an *allergic* reaction to sunscreen actives. This may be why more *allergies* to PABA are now reported.
With the number of UV filters permitted for use in cosmetics restricted to relatively few [illegible] materials, attaining ever higher ...that acts as a free radical scavenger. Other natural ingredients that are in use include [illegible] hydrogenated vegetable oils, tocopheryl acetate, [illegible] *Butyrospermum* *parkii* (Shea Butter) and Shea Butter Unsaponifiables.
Melanin continues to [illegible] manufacturers of suncare products and Tioxide has produced a [illegible] incorporating it. A...

...pH of 5-9. It is claimed [illegible] providing a natural-look tan on mammalian skin and [illegible] to be anti-*inflammatory* hypo- and hyperpigmentation.
Finally, for [illegible] a sunscreen on their skin, Ciba-Geigy has [illegible] and ultraviolet...

2/6,K/3 (Item 1 from file: 53)

00876886 FOODLINE ACCESSION NUMBER: 547033

Composition containing extracts of *Butyrospermum* *parkii* and the use as medicament or dietary supplement.
PATENT: WO 0103712 [illegible]7

Composition containing extracts of *Butyrospermum* *parkii* and the use as medicament or dietary supplement.
ABSTRACT: A composition comprising an extract or concentrate of *Butyrospermum* *parkii* useful as a dietary supplement or medicament for the suppression of *hypersensitivity* and/or *inflammatory* diseases. The active components include stigmasterol, avansterol, 24-methyl-[illegible]-7-enol, karitesterol A, karitesterol B and alpha-spinasterol.
DESCRIPTORS: *BUTYROSPERMUM* *PARKII* EXTRACT...

...*HYPERSENSITIVITY*; *INFLAMMATORY DISEASES

2/6,K/4 **(Item 1 from file: 73)**
DIALOG(R)File 73:(c) 2001 Elsevier Science B.V. All rts. reserv.

01451701 EMBASE No: 197[illegible]
Preliminary studies on nasal decongestant activity from the seed of the shea butter tree, *Butyrospermum* *parkii*
1979

Preliminary studies on nasal decongestant activity from the seed of the shea butter tree, *Butyrospermum* *parkii*

The seed of *Butyrospermum* *parkii* yields shea butter which according to local traditional healers relieves *inflammation* of the nostrils. Since there is as yet no absolutely satisfactory nasal decongestant in clinical use, it was decided to investigate the effects of shea...

2/6,K/5 **(Item [illegible])**
DIALOG(R)File 148:([illegible],2001 [illegible]. All rts. reserv.

09324537 SUPPLIER NUMBER: [illegible]4326 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Protecting skin and preventing [illegible]enoma (sun protection products)
Oct, 1996
WORD COUNT: 1814 LINE [illegible]52

... is concerned [illegible] sage users to stay in the sun longer, increasing [illegible] and also increasing the risk of an *allergic* reaction [illegible] actives. This may be why more *allergies* to PABA derivatives are reported.
With the number of UV [illegible] permitted for use in cosmetics restricted to relatively few established materials, attaining ever higher ...that acts as a free radical scavenger. Other natural ingredients that are in use include walnut [illegible] unsaturated vegetable oils, tocopheryl acetate, rhatania [illegible] to *Butyrospermum* *parkii* (Shea Butter) and Shea Butter Unsaponifiables.
Melanin continues [illegible] manufacturers of sun-care products and Tioxide has produced a [illegible] for ...

...pH of 5-9. It is claimed [illegible] for providing a natural-look tan on mammalian skin and hair [illegible] post-*inflammatory* hypo- and hyperpigmentation.(10)
Finally, for those who [illegible] to use a sunscreen on their skin, Ciba-Geigy has [illegible].

2/6,K/6 **(Item 2 from file: 1[illegible])**
DIALOG(R)File 148:(c)2001 The Gale Group. All rts. reserv.

07518215 SUPPLIER NUMBER: 15790712 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Cosmetic use of selected natural fats and oils.
August, 1994

protectants, skin lightening agents, skin soothing agents sunscreening agents and tanningantibacterials. anticaking, anticaries agents, anticellulites. antidandruff, antifungal, anti-*inflammatories*, anti irritants, antimicrobials.

antioxidants, astringents, antiperspirants. antiseptics, antistatic agents, antringents, binders, buffers, additional carriers, chelators, cell stimulants. cleansing agents, conditioners. deodorants, dipilatories, detergents, fats, emollients...

2/6,K/19 (Item 1 from file: 347)
DIALOG(R)File 347: (c) 2001 JPO & JAPIO. All rts. reserv.

00588650
SKIN CARE PREPARATIONS
AGENTS DE SOIN POUR LA PEAU
HAUTPFLEGEMITTEL
Publication Language: German
Filing Language: German
Fulltext Availability:
Detailed Description
Claims
Fulltext Word Count: 2658
Publication Year: 1998

Fulltext Availability:
Detailed Description

English Abstract
...and 10 wt.% preferably 0.1 to 5 wt.% of compounds prepared according to the invention increase the water capacity of the skin and significantly reduce the release of pro-inflammatory mediators.

French Abstract
...0,1 et 10 % en poids. Ces compositions permettent de renforcer la tonicite de la peau et de reduire sensiblement l'agitation de mediateurs pro- *inflammatoires*

Detailed Description
... and 10 wt.% preferably 0.1 to 5 wt.% of the compounds prepared according to the invention increase the water capacity of the skin and significantly reduce the release of pro-inflammatory ... (57) Zusammenfassung Kosmetische Zusammensetzung, insbesondere fur empfindlicher Haut in Form von Emulsionen oder Cremes, enthaltend in einem kosmetischen Fett- oder Olkomponenten naturliche Ole, Fette, Wachse ... Type S-75 : Hydrogenated Lecithin Mixture ... Cetyl Alcohol Generol 122N : Soy Sterol ... Triheptanoin ... Cetiol SB 45 *Butyrospermum* ... Cetiol V ... Oleyl Erucate Myritol 318 Capryl/Caprylic ... Type SB : Cetearyl Isononamoate Tufskin : Sorbitol und Yeast ... Biogum 1000 : Biosaccharide Gum (reich an...

2/6,K/20 (Item 2 from file: 347)
DIALOG(R)File 347: (c) 2001 JPO & JAPIO. All rts. reserv.

01365404
WPI Acc No: 2001-13625
Title Terms: PHARMACEUTICAL ... COMPRISE; TREAT;
HYPERSENSITIVITY

Pharmaceutical ... *Butyrospermum* *parkii*
e.g. for immediate ... type hypersensitivity* or
***inflammatory* ...**

Abstract (Last 6):
... Pharmaceutical composition or dietary supplement comprising an

extract or concentrate of *Butyrospermum* *parkii*, is new.
... i) an extract or concentrate of *Butyrospermum* *parkii* containing at least 5% (w/w) of Butyrospermum-triterpene fraction comprising (by w/...

...An INDEPENDENT CLAIM is also included for a method for the preparation of the pharmaceutical composition comprising *Butyrospermum* *parkii*.
...

...The pharmaceutical composition is in the form of a medication or dietary supplement which is useful for the regulation or suppression of *hypersensitivity* reactions (e.g. of the skin or mucous membranes) such as those presenting autoimmune diseases and inflammatory diseases (such as psoriasis, atopic dermatitis, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, rheumatoid arthritis or osteoarthritis), for alleviating pain or for preventing or treating prostatitis or begnign prostatic hypertrophy (claimed). In addition, the composition may also be useful for treating or preventing IgE mediated *allergic* reactions and conditions diabetes mellitus, multiple sclerosis, autoimmune hemolytic anemia, infections (e.g. viral or fungal), transplant rejection and asthma.
Technology Focus:
... Preparation: The concentrate of *Butyrospermum* *parkii* is mixed with a pharmaceutically acceptable carrier, and comprises up to 100% (w/w) (i) Butyrospermum-triterpene fraction comprising (by w/w%) (a) 10-40...
...Title Terms: *HYPERSENSITIVITY*; ... *INFLAMMATION*;

2/6,K/21 (Item ... from ...)
DIALOG(R)File 351: ... Derwent ... Ltd. ... reserv.

013051688
WPI Acc No: 2000-22... /2...0.
Title Terms: COSMETIC ... COMPOSITION; ...OTHING; SKIN; REDUCE; *INFLAMMATION*; LINE; WRINKLE; COMBAT; ... FREE; RADICAL; CONTAIN; GREEN; COFFEE; SHEA; BUTTER; ...TRACT

Cosmetic composition ... and reducing *inflammation*, lines and wrinkles ... free radicals, contains green coffee and shea butter extract

Abstract (Basic):
... A new product ... mixture of green coffee Coffea arabica L. ... Coffea ... and shea butter from the nut of *Butyrospermum* ...
... contains ... and ... butter are useful for healing and soothing ... skin ... the ... effects of oxygen free radicals, ... skin ... inflammation ... reducing aging and drying, the appearance ... including ... treating the hair, scalp, nails, and mucosa (all ... mod...
...Title Terms: *INFLAM...

2/6,K/22 (Item 1 from ...)
DIALOG(R)File ...(c) 20... ... reserv. All rts. reserv.

000969408
Title: COMPOSITIONS A USAGE ... OU DERMOPHARMACEUTIQUE CONTENANT UN MELANGE D'EXTRAIT DE CAFE VERT ... ET ... BEURRE DE KARITE
Publication Date: 19991217

Abstract:
...vert Coffea ... Coffea canephora L. Pierre a du beurre de karite obtenu a partir de la noix a karite ou *Butyrospermum* *parkii* Kotschy, ainsi ... utilisation dans des compositions a usage cosmetique ou dermo-pharmaceutique le produit resultant de cette

association est utilisée en tant que tel ..

...et la recherche d'effets [illegible] cutanes, y compris contre les consequences des effets [illegible] formes radicalaires de l'oxygene comme, par exemple, [illegible] cutanee, le vieillissement ou le dessechement prematuré de la peau, l'apparition des rides, ainsi que pour favoriser la protection des cheveux, du cuir chevelu...

2/6,K/23 (Item 1 from [illegible])
DIALOG(R)File 377:(c) 200[illegible] Ltd. All rts. reserv.

00607173 DERWENT ACCESS
A new African vege[illegible] of neurodermatitis and other skin d[illegible], 1994

A new African [illegible] the treatment of neurodermatitis and other skin diseases (Karita[illegible] *parkii*).

2/6,K/24 (Item 1 from [illegible] 399
DIALOG(R)File 399:(c) 200[illegible] CHEMICAL SOCIETY. All rts. reserv.

Pharmaceutical compo[illegible] extracts of Butyrospermum parkii and the use as medicament [illegible] supplement

2/6,K/25 (Item 1 from [illegible])
DIALOG(R)File 553:(c) 20[illegible] All rts. reserv.

04033339 B.W. [illegible] 79 33 39 (USE FORMAT 7 FOR FULLTEXT)
Shea butter [illegible] African [illegible].
Apr. '99
WORD COUNT: 2060 [illegible]

(USE FORMAT 7 FOR FULL[illegible]

TEXT:
... Shea butter [illegible] staple of African pharmacology. It acts as an effective [illegible] example. Used for its draining and anti-*inflammatory* [illegible] clothing in sprains and strains, and is a widely used [illegible]. This wonderful healing agent is also used for accele[illegible]

...Shea fruit is harvested [illegible] is made in an African village.

BOTANICAL
A hardy tree [illegible] Butyrospermum* *parkii* Kotsch) grows [illegible] centers [illegible] lives for a couple of centuries, [illegible] village is...hour and persists for eight [illegible] daily application maintains a very good moisturising [illegible] superficial layers of the skin.

ANTI-*INFLAMMATION
Shea butter is [illegible] alleviating rheumatism, which suggests an anti-[illegible] This has been substantiated (Tella) in a study [illegible]. Shea butter is tested on 33 volunteers against [illegible] containing...

...Pharmacopoeial, [illegible].

Nasal congestion [illegible] that can be relieved by two mechanisms: a vaso[illegible] anti-inflammatory*. Only the second mechanism applies for [illegible] never demonstrated any vasoconstrictor activity.

EFFICIENT RELEASE OF ACTIVE INGREDIENTS

8644206 Genuine Article#: 311T3 Number of References: 14
Title: Separation of sterols and triterpene alcohols from unsaponifiable fractions of three plant seed oils
Author(s): Li JG; Ho CT (REPRINT) ; Li H; Tao HR; Liu LQ
Corporate Source: RUTGERS STATE UNIV,DEPT FOOD SCI, 65 DUDLEY RD/NEW BRUNSWICK//NJ/08901 (REPRINT); RUTGERS STATE UNIV,DEPT FOOD SCI/NEW BRUNSWICK//NJ/08901; BEIJING NORMAL UNIV,DEPT CHEM/BEIJING 100875//PEOPLES R CHINA/
Journal: JOURNAL OF FOOD LIPIDS, 2000, V7, N1 (MAY), P11-20
ISSN: 1065-7258 Publication date: 20000500
Publisher: FOOD NUTRITION PRESS INC, 6527 MAIN ST, P O BOX 374, TRUMBULL, CT 06611
Language: English Document Type: ARTICLE
Geographic Location: USA; PEOPLES R CHINA
Subfile: CC AGRI--Current Contents Agriculture, Biology & Environmental Sciences
Journal Subject Category: FOOD SCIENCE & TECHNOLOGY
Abstract: Preparative HPLC was used to separate sterols and triterpene alcohols from the unsaponifiable matters in plant oils from Camellia weiningensis L., Brassica napus L. and Microtia sikkimensis. The isolated sterols and triterpene alcohols were acetylated and further purified by $AgNO_3$ impregnated silica gel preparative thin layer chromatography (TLC). The isolated acetyl derivatives of sterols and triterpene alcohols were identified by melting point, specific rotation, infrared and mass spectrometry. The sterols were brassicasterol, campesterol, stigmasterol, beta-sitosterol and Delta(5)-avenasterol, Delta(5,7)-avenasterol, Delta(7)-stigmastenol and alpha-spinasterol. The triterpene alcohols were cycloartanol, cycloartenol, 24-methylenecycloartanol cyclobranol, dammaradienol, tirucalla-7,24-dienol, **butyrospermol**, beta-**amyrin**, germanicol, Psi-4-taraxasterol and **lupeol**.
Identifiers--KeyWord Plus(R): VEGETABLE OILS
Cited References:
BROOKS CJW, 1971, V20, P427, [illegible]
DEV S, 1989, V1, P31, [illegible] TERPENOIDS
DEV S, 1989, V2, P75, [illegible] TERPENOIDS
HELLER SR, 1978, [illegible]
HILL RA, 1991, DICT STEROIDS
ITOH T, 1973, V5, [illegible]
ITOH T, 1974, [illegible]
ITOH T, 1980, [illegible]
LI H, 1998, V21, [illegible]
LI H, 1997, V19, P69, [illegible] CHINA
RADT F, 1956, ELSEVIERS ENCY ORGAN
RODD EH, 1953, P727, CHEM CARBON COMPOUND
UTSUMOYO T, 1983, V22, P789, PHYTOCHEMISTRY
YAN M, 1984, V5, P355, CHEM J CHINESE U
?

22/AB/1 (Item 1 from file: 155)

The 4-monomethylsterol and 4,4-dimethylsterol fractions were separated from the unsaponifiables of 20 vegetable oils by preparative thin layer chromatography, and their compositions were determined by gas liquid chromatography. Tentative identification of the individual components of these fractions was carried out by gas liquid chromatography and combined gas liquid chromatograph-mass spectrometry. Among 4-monomethylsterols, obtusifoliol, gramisterol, and citrostadienol occur abundantly in most of the oils. Cycloeucalenol is present in some of the oils as a major component of 4-monomethylsterols. Other 4-monomethylsterols tentatively identified are: lophenol, 24-methylenecycloartanol, 31-norcycloartenol, and 31-norlanostenol and/or 24-methylenecycloartenol. Among 4,4-dimethylsterols, cycloartenol and 24-methylenecycloartanol followed by beta-**amyrin** and cycloartanol are common constituents of the oils. **Butyrospermol**, alpha-**amyrin**, **lupeol**, and cycloartenol together with a 4,4-dimethylsterol, presumably lanostenol, occur in some of the oils. Cyclolaudenol is present in poppy seed oil. Besides these compounds, each of the oils contains some unidentified members of 4-monomethylsterols and 4,4-dimethylsterols. The methylsterol fraction of capsicum seed oil as compared with that of the other oils is characterized by its very high content of lophenol and cycloartanol together with some other members, presumably 31-norlanostenol, 4alpha-methylcholestanol, and lanostenol.

22/AB/2 (Item 1 from file: 34)

Abstract: Site-directed mutagenesis was carried out on two triterpene synthases, beta-**amyrin** (PNY), and **lupeol** (OEW) synthases, to identify the amino acid residues responsible for their product specificity. In addition to sequence comparison among known oxidosqualene cyclases, previous chimeric studies suggested that (MWCYCR263)-M-256 sequence of beta-**amyrin** synthase PNY ((MLCYCR260)-M-255 sequence of **lupeol** synthase OEW) would participate in product differentiation. To test this hypothesis, Trp259 (MWCYCR of PNY) was mutated to Leu (PNY W259L mutant). Functional expression in yeast and product analysis revealed that this mutant produced **lupeol** as a major product together with beta-**amyrin** in 2:1 ratio. Some minor amounts of products including **butyrospermol** were also produced. The corresponding Leu256 (MLCYCR of OEW) was mutated to Trp (OEW L256W). The mutant produced exclusively beta-**amyrin**, demonstrating that a single mutation converted **lupeol** synthase into beta-**amyrin** synthase. Therefore, Trp259 of **amyrin** synthase was identified to be the residue responsible for **amyrin** formation presumably through stabilization of the cation, while lack of this effect by Leu residue may terminate the reaction at lupenyl cation stage. In further mutation studies, Tyr residue (MWCYCR in PNY and MLCYCR in OEW) conserved in all of the OSCs producing pentacyclic triterpenes was mutated into His which is found in all of those producing tetracyclic carbon skeletons to investigate the role of this Tyr261 of PNY. PNY Y261H mutant produced dammara-18,21-dien-3 beta-ol (as a 3:5 mixture of E/Z isomer at Delta 18) together with a minor amount of dammara-18(28),21-dien-3 beta-ol, demonstrating that Tyr261 of beta-**amyrin** synthase plays an important role in producing pentacyclic triterpenes presumably by stabilization of the cation intermediates generated after substrate activation.

22/AB/3 (Item 2 from file: 34)

Abstract: Preparative HPLC was used to separate sterols and triterpene alcohols from the unsaponifiable matters in plant oils from Camellia weiningensis L., Prassiana fulcea L. and Microula sikkimensis. The isolated sterols and triterpene alcohols were acetylated and further

purified by AgNO3 impregnated silica gel preparative thin layer chromatography (TLC). The isolated acetyl derivatives of sterols and triterpene alcohols were identified by melting point, specific rotation, infrared and mass spectrometry. The sterols were brassicasterol, campesterol, stigmasterol, beta-sitosterol and Delta(5)-avenasterol, Delta(7)-avenasterol, Delta(7)-stigmastenol and alpha-spinasterol. The triterpene alcohols were cycloartanol, cycloartenol, 2 [illegible] cyclobranol, dammaradienol, tirucalla-7,24-dien[illegible] [illegible]ol *. beta-**amyrin**, germanicol, Psi-4-taraxasterol [illegible] *[illegible] *.

?

```
DIALINDEX(R)
   (c) 2001 The Dialog Corporation plc

*** DIALINDEX search results display in an abbreviated ***
*** format unless you enter the SET DETAIL ON command. ***
?sf allmedph
   You have 214 files in your file list.
   (To see banners, use SHOW FILES command)
?s butyrospermum(w)parkii

Your SELECT statement is:
   s butyrospermum(w)parkii

          Items   File
          -----   ----
             18     5: [illegible]  1969-2001/Jul W2
              3     [illegible]  -2001/Jul W2
             13     [illegible] Jun
              6    16: [illegible] PROMT(R) 1990-2001/Jul 11
              1    20: [illegible] 1907-2001/Jul 12
              5    34: [illegible] (R) Cited Ref Sci 1990-2001/Jul W2
              2    40: [illegible] 1975-2001/May
              1    47: [illegible] -2001/Jul
             38    [illegible] CAB Abstracts 197[illegible]01/Jun
             16    51: [illegible] Abs 1969-2001/Sep W2
              2    [illegible] [illegible]ence &
                   [illegible] /Jul 11
              3    [illegible] Legislation_1972-2001/JUN
                   W1
              2    68: Env[illegible]-2001/Jun
              3    71: ELSEVIER BIOBASE 1994-2001/Jul W2
              4    73: EMBASE [illegible] W2
              2    74: [illegible]0-2001/Jun
              1    [illegible] [illegible]/Jun W3
              1    [illegible] [illegible]ech Abs 1983-2001/May
              1    [illegible]1/Jun
              2    112: Jane's [illegible]ews 1998-2001/Jul 11
      Examined  50 files
              2    14  [illegible] Index_1983-2001/May
             11    [illegible] W2
             10    [illegible]de & Industry DB_1976-2001/Jul 11
              1    [illegible]-2001/Jul W3
              6    [illegible] Dec
              3    [illegible] /May
              1    [illegible] W2
              1    [illegible]5-2001/Jul 10
              1    185: [illegible] Online(R)_1978-2001/Jun
             12    203: AGRIS [illegible]/Dec
              3    285: Biosis [illegible]-1998/Aug W1
              1    305: [illegible]racts_1980-2001/Jun W4
      Examined 100 files
              1    [illegible] Abs_1970-2001/May
              2    319: [illegible] e 1984-2001/Jul 12
              5    348: [illegible] S_1978-2001/Jul W01
             18    [illegible] 9-2001/UB=20010628, UT=20010621
             10    [illegible] -2001/UD,JM &UP=200138
              2    [illegible] -2001/BOPI 200127
              1    [illegible] 964-1982
              1    [illegible] 85-2001/Jul W4
             15    [illegible] -2001/UD=13503
              [illegible]  [illegible] Full Sc _1974-1989/Dec
              9    [illegible] Search(R) 1990-2001/Jul W3
      Examined 150 files
              2    55[illegible]: [illegible] Full Text_1982-2001/May
              1    636: Gale Group Newsletter DB(TM) 1987-2001/Jul 11
              1    652: US Patents Fulltext_1971-1979
              2    653: US Pat.Fulltext_1980-1989
              1    654: US PAT FULL_1990-2001/Jul 10
```

```
      Examined 200 files

   48 files have one or more items; file list includes 214 files.

?sf hits
   You have 48 files in your file list.
   (To see banners, use SHOW FILES command)
?s butyrospermum(w)parkii a  (?)l~ g? or inflamm? or hypersensitiv? or hyper()sensitiv
?)

Your SELECT statement is:
   s butyrospermum(w)parkii and (?)l erg? or inflamm? or hypersensitiv? or
hyper()sensitiv?)

          Items   File
          -----   ----
              2    16: Ga  Gro o P  DMT(R) _1990-2001/Jul 11
              1    53: FOO LINE(R) : Food Science &
                       Techno gy 1972-2001/Jul 11
              1    73: EMP S  97  -2001/Jul W2
              4   148: Gal  roup  a e & Industry DB_1976-2001/Jul 11
              1   15.: GBD  26 .001/Jul W3
              1   156: Ox  1  5- .00/Dec
              2   348: EUR  NTS_1978-2001/Jul W01
             10   349: PC  98 -.01/UB=20010628, UT=20010621
              2   351: De  -2001/UD,UM &UP=200138
              1   37 : ate s  .001/BOPI 200127
              1   376: Derwe  Drug File_1964-1982
              1   377: Derwent Drug File_1983-2001/Jul W4
              1   399: CA SEARCH(R) 1967-2001/UD=13503
              1   5.5: Wi  Bu s. FullText_1982-2001/May

   14 files have one o  mo  ite s;  e list includes 48 files.

?save temp
Temp SearchSave "TD174" stored
?rf
Your last SELECT statement was
   S BUTYROSPERMUM(W)PARKII AND  AL  G  OR INFLAMM? OR HYPERSENSITIV? OR -
HYPER()SENSITIV?)
Ref         Items   File
---         -----   ----
N1             10   349: PC  1983-2001/UB=20010628, UT=20010621
N2              4   148: Ga  roup  a e & I dustry DB_1976-2001/Jul 11
N3              2    16: Gal  roup  (R)M  )_1990-2001/Jul 11
N4              2   348: EUROPA  PA NTS_1978-2001/Jul W01
N5              2   351: De  -2001/UD,UM &UP=200138
N6              1    53: F  N  d Science & Technology_1972-2001/J
N7              1    73: E  1/J  W2
N8              1   155: a  -2001/Jul W3
N9              1   156: Ox  5 2000/Dec
N10             1   371: Fe  1961-2001/BOPI 200127
   14 files have one o  mo  ite s  e list includes 48 files.

       - Enter P or  GF  ore
?b hits
       12jul01 14:2  J  ssi n D533.2
            $4.33  4  1  Fi e1
     $4.33  Estimated cost
     $0.45  TYMNET
     $4.78  Estimated c
     $4.82  Estimated  st  .6.8 DialUnits


SYSTEM:OS  - DIALOG OneS ar
  File  16:Gale Group P MT(R  99 -  01/Jul 11
        (c) 2001 The Gale Group
  File  53:FOODLINE(R). Food Scie ce & Technology  1972-2001/Jul 11
```

```
        (c) 2001 LFRA
  File  73:EMBASE  1974-2001/Jul W2
        (c) 2001 Elsevier Science B.V.
*File  73: For information about Explode feature please
see Help News73.
  File 148:Gale Group Trade & Industry DB  1976-2001/Jul 11
        (c)2001 The Gale Group
  File 155:MEDLINE(R)  1966-2001/Jul W3
        (c) format only 2001 Dialog Corporation
*File 155: This file has been reloaded. Accession numbers have changed.
 Please see Help News155 for details.
  File 156:Toxline(R)  1965-1981/Dec
        (c) format only 2001 Dialog Corporation
*File 156: This file is closed (1965-1981). For toxicology search
strategy and changes after 1981, see Help News156.
  File 348:EUROPEAN PATENTS  1978-2001/Jul W01
        (c) 2001 European Patent Office
  File 349:PCT Fulltext  1983-2001/UB=20010628, UT=20010621
        (c) 2001 WIPO/Minesoft
  File 351:Derwent WPI  1963-2001/UD  (20010638
        (c) 2001 Derwent Info Ltd
*File 351: Price changes and /c 01 are see HELP RATES 351.
 72 Updates in 2001. Please see News 3 for details.
  File 371:French Patents  1961-2001/ 20010427
        (c) 2001 INPI. All rights reserved.
  File 376:Derwent Drug File
        (c) 1995 Derwent Info
  File 377:Derwent Drug File Co  1  W04
        (c) 2001 Derwent Info
  File 399:CA SEARCH(R)  1967-3
        (c) 2001 AMER CHEM SOCY
*File 399: Use is subject to your user/customer agreement.
RANK charge added; see Help Rates.
  File 553:Wilson Bus. Abs  1982-2001/May
        (c) 2001 The HW Wilson Co

      Set  Items  Description
      ---  -----  -----------
?exs
Executing TD174
Hilight option is not available in file(s) 399
HILIGHT set on as '**'
KWIC is set to 50.
KWIC option is not available in file 399
            178  BUTAMIDE
            102  BUTAMIDES
             83  BUTYRAMIDE
         364040  ALLERG?
         684288  INFLAMM?
         203358  HYPERSENSITIV?
          40694  HYPER
        1953555  SENSITIV?
            638  HYPERSENSITIVITY
      S1     29  (BUTAMIDE OR BUTAMIDES OR BUTYRAMIDE) AND (ALLERG? OR INFLAMM? OR
                 HYPERSENSITIV? OR (HYPER() SENSITIV?)
?rd
>>>Duplicate detection is not supported for file 348.
>>>Duplicate detection is not supported for file 349.
>>>Duplicate detection is not supported for file 351.
>>>Duplicate detection is not supported for file 371.

>>>Records from unsupported files cannot be retained in the RD set.
...completed examining records
      S2     25  RD (unique items)
?t s2/6,k/all
>>>KWIC option is not available in file(s): 399

 2/6,K/1     (Item 1 from file: 16)
```

WORD COUNT: 7789 LINE COUNT: 00654

... 6), which in turn can be further elongated and desaturated to docosapentaenoic acid (C22:5n-6). The cyclooxygenase derivatives of C20:3n-6 are less *inflammatory* as a rule, than those derived from AA. This is one of the reasons that LA is commonly endowed with antiinflammatory properties. This conversion of...oil is used in cosmetics as an occlusive and bodying agent in creams and gels.

Shea butter, obtained from the fruit of the karite tree, *Butyrospermum* *parkii*, contains a high level of oleic acid, and it could be classified as a mono-unsaturated triglyceride. In cosmetics, it is widely used as an...choline. The acyl group in the 2 position is subject to enzymatic hydrolysis by phospholipase [A.sub.2] which, in body membranes, commonly releases an [illegible]* unsaturated fatty acid. The remaining monoacyl derivatives [illegible] lecithin.

The major [illegible] stipid is crushed dried soybeans, extracted [illegible]

2/6,K/7 (Item 3 from file: [illegible])
DIALOG(R)File 148:(c)2001 [illegible] rts. reserv.

06787106 SUPPLIER NUMBER: [illegible] (USE FORMAT 7 OR 9 FOR FULL TEXT)
Waxing natural. (evaluation [illegible] waxes)
Nov, 1993
WORD COUNT: 1787 LINE COUNT: [illegible] 135

... skin emollient and [illegible] time providing a protective barrier. It can be used universally [illegible] lsions and lipsticks.

The debate continues [illegible] *allergy* of lanolin, with most of the evidence pointing to [illegible] a problem. Dr Ian Steel puts forward an excellent defence [illegible]

...the old day , when records [illegible] d to revolve at 78rpm, it was a fundamental constituent of their composition.

Recent Waxes

Recent waxes include [illegible] Butyrospermum* *parkii*), mango butter (Mangifera indica), [illegible] (Shorea stenoptera), babassu palm fat (Orbygnia martiana) [illegible] Elaeis guineensis).

West Afri [illegible]

2/6,K/8 (Item [illegible])
DIALOG(R)File 348:(c) [illegible] ent Office. All rts. reserv.

01288417
Cosmetic and dermatologic [illegible]gens in the form of O/W-macro or -micro-emulsions [illegible]
Kosmetische [illegible] Lichtschutzformulierungen in Form von O/W-Makroemulsionen oder [illegible] Mikroemulsionen, mit einem Gehalt an Sheabutter
Filtres solaires [illegible] dermatologiques sous forme de macro- ou micro-emulsions de type [illegible] ant du beurre de karite
LANGUAGE (Publication, [illegible] ication): German; German; German
FULLTEXT AVAILABILITY
Available Text Language [illegible] unt
CLAIMS A (Ger [illegible]
SPEC F [illegible]
Total word count [illegible] 6
Total word count - [illegible]
Total word count - [illegible] 6

...SPECIFICATION Verlust von [illegible] gebenen Stoffen (z.B. Wasser, naturliche Fette, Elektrolyte) gestort [illegible] wiederhergestellt wird.

Wird diese Funktion [illegible] zu verstarkter Resorption toxischer oder [illegible] und zum Befall von Mikroorganismen und als Folge zu [illegible] allergischen* Hautreaktionen kommen.

Ziel der Hautpflege [illegible] reinen, den durch tagliche Waschen

verursachten Fett- und Wasserverlust der Haut auszugleichen. Dies ist gerade dann wichtig, wenn...

...Substanzen, also Emulgatoren, notig. An sich ist die Verwendung der ublichen kosmetischen Emulgatoren vollig unbedenklich. Dennoch konnen Emulgatoren, wie letztlich jede chemische Substanz, im Einzelfalle *allergische* oder auf Uberempfindlichkeit des Anwenders beruhende Reaktionen hervorrufen. So ist bekannt, das bei manchen besonders empfindlichen Personen bestimmte Lichtdermatosen durch gewisse Emulgatoren und gleichzeitige [illegible]kung...Menge an Sheabutter, den Nachteilen des Standes der Technik abhelfen.

Sheabutter (auch: Sheafett, Karitefett oder Caritefett, Galambutter) ist ein naturliches [illegible] der Pflanze *Butyrospermum* *parkii*, dem afr[illegible]baum, gewonnen wird und in kommerziellen Me[illegible]herweise enthalt Sheafett 89 bis 98 Gew.-% Triglyceride, G[illegible] r und freie Fettsauren sowie einen...

2/6,K/9 (Item 2 fr[illegible] 34
DIALOG(R)File 348:(c) [illegible] t C[illegible]ice. All rts. reserv.

01245757
Oil-in-water preparations for cosmetic or dermatologic use
Kosmetische oder dermatologische Zubereitungen von Typ Ol-in-Wasser
Preparations cosmetiques ou dermatologiques du type huile dans l'eau
LANGUAGE (Publication,Procedural,Application): German; German; German
FULLTEXT AVAILABILITY:
Available Text Language Update Word Count
CLAIMS A (German) [illegible]
SPEC A (German) [illegible]
Total word count - document A [illegible]
Total word count - document [illegible]
Total word count - documents A + B 9220

...SPECIFICATION Mengen [illegible] m[illegible] Emulgatoren erforderlich sind (z. B. 3 Gew. [illegible] a[illegible] auch Emulgatoren - wie letztendlich jede chem[illegible] inzelfall *allergische* oder auf Uberem[illegible] Reaktionen hervorrufen konnen (obw[illegible] etischen Emulgatoren i. a. naturlich vollig [illegible] wunschenswert...Sheabutter, auch Karitefett oder [illegible] (CAS-Nr. 68920-03-6). Sheabutter ist das Fett der Samen [illegible] Familie der Sapotaceae angehorenden Pflanze *Butyrospermum* *Pa[illegible]* [illegible] zu etwa 34 bis 45 Gew.-% aus festen Fettsauren (vornehmlich [illegible] und zu etwa 50 bis 60 Gew.-% aus flussigen Fettsauren (vor[illegible] saure enthaltend...

2/6,K/10 (Item [illegible] 9
DIALOG(R)File 349:(c) [illegible] rts. reserv.

00774939
LYSINE OXIDASE LINKAGE OF [illegible] SSUE
LIAISON D'AGENTS A[illegible] E
Publication Language: [illegible]
Filing Language: [illegible]
Fulltext Availability:
Detailed Description
Claims
Fulltext Word Count: [illegible]188
Publication Year: 2001

Fulltext Availability:
Detailed Description

Detailed Description
... oleifera; bre[illegible]; butyl acetyl ricinoleate; butyl isostearate; butyl myristate, butyl oleate; butyl stearate; butylene

glycol dicaprylate/dicaprate; butylene glycol montanate; butyloctyl beeswax; butyloctyl oleate; *butyrospermum* *parkii*; butyroyl trihexyl citrate; butyrum; buxus chinensis; C 10- 18 triglycerides; C I 1- 15 pareth- 12 stearate; C I 1- 15 pareth-3 oleate; C...Rutin; Saffloweramidopropyl Ethyldimonium Ethosulfate; Salicylic Acid; Selenium Sulfide; Sericin; Serine; Serum Albumin; Serum Protein; Sesame (Sesamum Indicum) Oil Unsaponifiables; Sesamidopropylamine Oxide; Sesamidopropyl Betaine; Shea Butter (*Butyrospermum* *Parkii*) Unsaponiflables; Shellac Wax; Silicone Quaternium-1; Silicone Quaternium-2; Silicone Quaternium-3; Silicone Quaternium-4; Silicone Quaternium-5; Silicone Quaternium-6; Silicone Quaternium-7; Silicone...As mentioned above, the agent may be a pharmaceutical agent.

Examples of categories of pharmaceutical agents include: analgesic; amino acid; antagonist; anti-acne agent; anti-allergic*; anti-asthmatic; antibacterial; anticholinergic; antifungal; antiglaucoma agent; antihistamine; anti-infective, local; anti-infective, topical; anti-*inflammatory*; antikeratinizing agent; antimicrobial; antimycotic; antineoplastic, antineutropenic; antioxidant; antiproliferative; antipruritic; antiseborrheic; carbonic anhydrase inhibitor; cholinergic; cholinergic agonist; diagnostic aid; fluorescent agent; glucocorticoid; hair growth stimulant; histamine...Nitromersol; Octenidine Hydrochloride; Oxychlorosene; Oxychlorosene Sodium; Parachlorophenol, Camphorated; Potassium Permanganate; Povidone-Iodine; Sepazonium Chloride; Silver Nitrate; Sulfadiazine, Silver; Symclosene; Thimerfonate Sodium; Thimerosal Troclosene Potassium.
Anti-*inflammatory*: Alclometasone Dipropionate; Algestone Acetonide; Alpha Amylase

2/6,K/11 (Item from file: 349)
DIALOG(R)File 349:(c) 2003 [illegible] Derwent. All rights. reserv.

00774894
LINKAGE OF AGENTS TO TISSUE
LIAISON D'AGENTS AVEC DES TISSUS
Publication Language: English
Filing Language: English
Fulltext Available:
  Detailed Description
  Claims
Fulltext Word Count: [illegible]
Publication Year: 2003

Fulltext Availability:
  Detailed Description

Detailed Description
... oleifera; brevidens; butyl acetyl ricinoleate; butyl isostearate; butyl myristate; butyl oleate; butyl stearate; butylene glycol dicaprylate/dicaprate; butylene glycol montanate; butyloctyl beeswax; butyloctyl oleate; *butyrospermum* *parkii*; butyroyl trihexyl citrate; butyrum; buxus chinensis; C 10- 18 triglycerides; C I 1- 15 pareth- 12 stearate; C I 1- 15 pareth-3 oleate; C...mentioned above, the agent may be a pharmaceutical agent. Examples of categories of pharmaceutical agents include: analgesic; amino acid; antagonist; anti acne agent; anti-allergic; anti-asthmatic; antibacterial; anticholinergic; antifungal; antiglaucoma agent; antihistamine; anti-infective; anti-infective, local; anti-infective, topical; anti-*inflammatory*; antikeratinizing agent; antimicrobial; antimycotic; antineoplastic, antineutropenic; antioxidant; antiproliferative; antipruritic; antiseborrheic; carbonic anhydrase inhibitor; cholinergic; cholinergic agonist; diagnostic aid; fluorescent agent; glucocorticoid; hair growth stimulant; histamine...Nitromersol; Octenidine Hydrochloride; Oxychlorosene; Oxychlorosene Sodium; Parachlorophenol, Camphorated; Potassium Permanganate; Povidone-Iodine; Sepazonium Chloride; Silver Nitrate; Sulfadiazine, Silver; Symclosene; Thimerfonate Sodium; Thimerosal Troclosene Potassium.

Anti-*inflammatory*: Alclofenac; Alclometasone Dipropionate; Algestone Acetonide; Alpha Amylase; Amcinafal; Amcinafide; Amfenac Sodium; Amiprilose Hydrochloride; Anakinra; Anirolac; Anitrazafen; Apazone; Balsalazide Disodium; Bendazac; Benoxaprofen; Benzydamine Hydrochloride; Bromelains; Broperamole...

2/6,K/12 (Item 3 from file: 34)
DIALOG(R)File 349:(c)200 t. All rts. reserv.

00773330
TREATMENT AND COMPOSITION FOR ... ANTI-AGING BENEFITS BY CORNEUM PROTEASE ACTIVATION
TRAITEMENT ET COMPOSITION ... ANT DES EFFETS ANTI-VIEILLISSEMENT PAR ACTIVATION DES PROTEA... CHE CORNEE
Publication Language: English
Filing Language: English
Fulltext Availability:
Detailed Description
Claims
Fulltext Word Count: 9431
Publication Year: 2001

Fulltext Availability:
Detailed Description

Detailed Description
... as "epidermal ce... amples of injuries which can increase epidermal ... ude abrasion, chemical damage, pH extremes, excessive ... or allergic* or non-*allergic* contact irritation... e too severe, the increased replication will resu... ic" epidermis and a thickened, poorly functionin... h...rose oil, safflower (carthamus tinctorius) o... , salicylic acid, sandalwood (San... r... otein, sesame (sesamum indicum) oil, ... e kii..., silk powder, sodium chondroitin s... ...um ...ronat... sodium lactate, sodium palmita... ... poly...utarnate, sodium stearate, soluble collagen, ...an...l rate. .etc.), vitamins (i.e. A, C, E, K, etc.). ... ...inc, calcium, selenium, etc.), anti-irritants (e.g. ... ...te...idal anti-*inflammatories*, etc.), antimicrobial agen... ...losan, etc.), botanical extracts (e.g. aloe vera, chamomil... ...xtract, ginkgo bibloba, ginseng, rosemary, etc.), ... and co... ...ts...

2/6,K/13 (Item ... fro...
DIALOG(R)File 349:(c) 200... ...t. All rts. reserv.

00771732
COMPOSITION CONTAINING ... ...TYROSPERMUM* *PARKII* AND THE USE AS MEDICAMENT OR DIETARY ...
COMPOSITION CO...ENANT ... DE BUTYROSPERMUM* *PARKII* ET UTILISATION EN TA... ...UPPLEMENT ALIMENTAIRE
Publication Langua...
Filing Language: E...
Fulltext Availabilit...
Detailed Descript...
Claims
Fulltext Word Coun... 1094
Publication Ye...

COMPOSITION CONTAINING A FRAC... ...TYROSPERMUM* *PARKII* AND THE USE AS MEDICAMENT OR DIETARY SUPPLE...
COMPOSITION CONTENANT DES ...TRAITS DE *BUTYROSPERMUM* *PARKII* ET UTILISATION EN TANT QUE ...ENT OU SUPPLEMENT ALIMENTAIRE
Fulltext Availability:

Detailed Description
Claims

English Abstract

The present invention relates to a composition comprising an extract or a concentrate of *Butyrospermum* *parkii* as a dietary supplement or a pharmaceutical composition and to the use of such compositions for the preparation of a medicament or dietary supplement for the suppression of *hypersensitivity* and *inflammatory* reaction. The composition may optionally be formulated with a pharmaceutically acceptable carrier for systemic or topical administration. More specifically, the invention relates to a dietary supplement or a pharmaceutical composition comprising an extract or a concentrate of *Butyrospermum* *parkii* , wherein said extract or concentrate contains Butyrospermum-triterpenes and optionally the sterol ... avanasterol, 24-methyl-cholest-7-... a, karitesterol B and &alpha...

French Abstract

La presente invention concerne une composition contenant un extrait ou un concentre de *Butyrospermum* *parkii* en tant que supplement alimentaire ou une composition pharmaceutique ainsi que l'utilisation de ces compositions dans la preparation d'un medicament ou d'un supplement alimentaire destine a la suppression de la reaction d'hypersensibilite et/ou *inflammatoire* La composition peut etre formulee facultativement avec un excipient acceptable sur le plan pharmaceutique destine a une administration systemique ou topique. Plus specifiquement, l'invention concerne un supplement ... une composition pharmaceutique contenant un extrait ou ... de *Butyrospermum* *Parkii* , dans lequel ledit extrait ou ... des Butyrospermum-Triterpenes et facultativement ... sterol, avanasterol, 24-methyl-cholest-7-enol, karit... ol A, karitesterol B...

Detailed Description

COMPOSITION CONTAINI... ...OSPERMUM* *PARKII*
AND THE USE ...

FIELD OF THE ...

The present in... relates to a dietary supplement or a pharmaceutical composition for s... ic ...op... l administration comprising an extract or a concentrate of ... *parkii* optionally formulated with a pharmaceutically ... r for systemic or topical administration. More ... e invention relates to a dietary supplement or a ... ition comprising an extract or a concentrate of ... wherein said extract or concentrate co... s butyrospermol, lupeol, parkeol, germanic..., ... ylene dammarenol, (x-amyrin and P-amyrin and ...

...B and a spinasterol ... of such compositions for the preparation of a medi... y supplement for the suppression of *hypersensitivity* ... reaction.

BACKGROUND OF T... NVE...

Hypersensitivity ... a ...ed reactivity in which the body react... ...ed... response to a substance (antigen). *Hyper... ...y* ... caused by exogenous or enclogenous antigens.

Hypersensitivity ... a large number of diseases. Among these, *allergic* and ... ...ases are of great importance. A classification of ... ...ases is given in the textbook Clinical Medici... (... , M. : "Clinical Medi cine", 3rd edition, p. 147 ..., ...ill, London).

Type I *hypersensitivity* reactions (IgE mediated *allergic* reactions) are caused by *allergens* (... ic exogenous antigens), e.g. pollen, house dust, animal dand... ...ds, etc. Aller gic diseases in which type I reactions play a signi... nt role include asthma, eczema (atopic

dermatitis), urticania, *allergic* rhinitis and anaphylaxis.

Type I I *hypersensitivity* reactions are caused by cell surface or tissue bound antibodies (IgG and IgM) and play a significant role in the pathogenesis of myasthenia gravis, Good pasture's syndrome and Addisonian pernicious anaemia.

Type III *hypersensitivity* reactions (immune complex) are caused by autoantigens or exogenous antigens, such as certain bacteria, fungi and parasites. Diseases in which type III *hypersensitivity* reactions play a significant role include ... hematosus, rheumatoid arthritis and glomerulonephritis.

Type IV *hypersensiti ... (delayed) are caused by cell or tissue bound antigen

This type of *hyper... ...ficant role in a number of conditions, e.g. graft ve... ... leprosy, contact dermatitis and reactions due to ins... ...tes

A number of drug classes ... ...va... ...ble for the treatment of *hypersensitivity* reac... ...

Among these the cortico... ... ...s the most widely used drugs. Corticosteroids primari... ...t... ...ir pharmacological action by non-selectively inhibiting ... ... and proliferation of different classes of immune cells resp... ... suppression of *hypersensitiv* ity reactions. Unfortunately, th... ...osteroids are associated with a number of serious side effe... ... immuno-suppression, osteoporosis and skin atrophy.

The African tree...such ... ...ld be maximum 1 % (w/w).

FIR 2770400 (WO 9... ... ... dermopharmaceutical compositions ... ... f *Butyrospermum* *parkii*. T... ... ...ut ... ...f the chemical components of the flowers, but to ... ...inv... ...or best ... ...wledge the flowers do not contain any substantial amo... ...

...the patent butyro... ...e ... ...ined from Butyrospermumparkii.

To the inventor's best knowl... ...e pharmaceutical compositions according to the invention ... ... extracts or concentrates of *Butyrospermum* *parkii* ... ... further detail in the following have never been disclose... ... ...he literature.

SUMMARY OF THE INVENTION

It has been found by t... ...ventor that a composition comprising an extract or a co... ...m* *parkii*, said extract or concentrate compri... ... ...rospermum-triterpene fraction, sa... ... ...m the group consisting of butyrosperm... ... ...rke...

...triterpenes and st... ...s ... ...he form of free alcohols or esters thereof, especially ... ...cetic acid or fatty acid esters significantly suppre... ...ivity* reactions when used in systemic administration, ..., said extract or concentrate comprises a pharmac... ... ...al ... arrier for systemic administration.

Furthermore, it ... ...nt inventor that a pharmaceutical compo... ...tion co... ...ng at least 5% Butyrospermum-triterpenes and op... ...ally a pharmaceutically acceptable carrier when applied topically significantly inhibits *inflammation* or *hypersensitivity* o... ... ...ous membranes. This is surprising because such effects are not obtainable with the lower levels of Butyrospermum triterpenes ... ...rough the...mentioned above, the

pharmaceutical compositions and dietary supplements according to the invention can be employed for the following therapeutic applications: Immunomodulation.

Treatment or prevention of *hypersensitivity* diseases.

Treatment or prevention of *inflammation* or *hypersensitivity* of the skin.

Treatment or prevention of *inflammation* or *hypersensitivity* of mucous membranes.

Treatment or prevention of *allergic* reactions and conditions.

Treatment or prevention of [illegible].

Alleviation of pain.

Accordingly, the present invention provides a dietary supplement or a pharmaceutical composition comprising:

1. an extract or a concentrate of *Butyrospermum* *parkii*, said extract or concentrate comprising [illegible] 5% of a Butyrospermum-triterpene fraction, said triterpenes being selected from the group consisting of butyrospermol, lupeol ..

...skin or mucous membrane.

Furthermore, the present invention provides the use of a composition for systemic administration comprising an extract or a concentrate of *Butyrospermum* *parkii* as described above and optionally a pharmaceutically acceptable carrier for systemic administration for the preparation of a medicament for immunomodulation in a mammal, for the suppression of hypersensitivity reactions in a mammal, such as IgE mediated *allergic* reactions or autoimmune reactions in a mammal, and for the alleviation of pain in a mammal.

Thus, according to the invention a composition comprising an extract or a concentrate of *Butyrospermum* *parkii* as described above for systemic administration and a pharmaceutically acceptable carrier for systemic administration may be used in a method for the treatment or prevention of a hypersensitivity reactions in a mammal, said method comprising administering said composition to said mammal; and the invention comprises the use of said composition for the preparation of a medicament for the treatment or prevention of *hypersensitivity* diseases in a mammal

Also, according to the invention a composition comprising an extract or a concentrate of *Butyrospermum* *parkii* as described above for systemic administration and a pharmaceutically acceptable carrier for systemic administration may be used in a method for the treatment or... the treatment of [illegible] disorders in a mammal.

Further, according to the invention a composition comprising an extract or a concentrate of *Butyrospermum* *parkii* as described above for systemic administration and a pharmaceutically acceptable carrier for systemic administration may be used in a method for the treatment or prevention of IgE mediated *allergic* reaction or condition in a mammal, said method comprising administering said composition to said mammal; and the invention comprises the use of said composition for the preparation of a medicament for the treatment or prevention of IgE mediated *allergic* reactions and conditions in a mammal.

Also, according to the invention a composition comprising an extract or a concentrate of *Butyrospermum* *parkii* as described above for systemic administration and optionally a pharmaceutically acceptable carrier for

systemic administration can be used in a method for the alleviation of...

...comprising at least 5% by weight Butyrospermum-triterpenes and optionally a pharmaceutically acceptable carrier can be used in a method for the treatment or prevention of *inflammation* or *hypersensitivity* of the skin or mucous membranes in a mammal, said method comprising administering said composition topically to said mammal; and the invention comprises the use of said composition for the preparation of a medicament for the treatment or prevention of *inflammation* or *hypersensitivity* of the skin or mucous membranes in a mammal.

Also, according to the invention, a pharmaceutical composition comprising at least 5% Butyrospermum-triterpenes optionally...

...INVENTION

It has been found by the present inventor that a dietary supplement or a pharmaceutical composition comprising:

1. an extract or a concentrate of Butyrospermum* *parkii*, said extract or concentrate comprising at least 5% of a Butyrospermum-triterpene fraction, said triterpenes being selected from the group consisting of butyrospermol, lupeol, ... acid or fatty acid esters; and optionally
3. a pharmaceutically acceptable carrier said carrier being suitable for either systemic or topical administration, significantly suppresses *inflammation* or *hypersensitivity* reactions.

Said pharmaceutical composition may be adapted for either systemic administration or for topical administration to the skin or mucous membrane.

In example 1 the ... extract of a composition according to the invention ... enable measurement of *hypersensitivity* ... the mouse. In this experiment the composition ... the invention showed a significant effect (at 50 mg/kg) comparable to that ... phosphamide...

...Thus, the therapeutic index of the composition of the invention is far superior to that of cyclophosphamide.

When applied topically ... composition inhibits *inflammation* or ... sensitivity reactions of the skin or mucous membranes.

In example 2 the topical anti-*inflammatory* effects of different compositions according to the invention are compared to an ordinary composition (control) ... shea butter corresponding to 2% Butyrospermum-triterpenes. ... compositions according to the invention containing 10-30% butyrospermum-triterpenes dose-dependently inhibit the *inflammation* ... The control has no anti-*inflammatory* ... This is surprising because such effects are not obtainable with ... butyrospermum-triterpenes that, through the ... have ...

...far been used in topical ... cosmetic products.

The compositions of the invention ... either topical or systemic administration ... good anti-*hypersensitivity* and anti-*inflammatory* ... surprisingly good safety profile. Thus, the compositions of the invention are ... virtually non-toxic and yet very therapeutically effective. The inventor puts forward the hypothesis that the very favourable therapeutic index of the compositions of the invention compared to ... chemical anti-*hypersensitivity* drugs is due to the ... nature of the compositions of the invention, giving a lower total ... to the body of any...

...the composition ...
More specifically ... the above mentioned compositions of the invention provide the following ... physiological effects upon administration to the

living organism:

Immunomodulation.

Suppression of *hypersensitivity* reactions.

Inhibition of *inflammation* or *hypersensitivity* of the skin. This effect can be obtained in relation to any skin disease or in relation to any disease giving rise to such symptoms of the skin, such as atopic dermatitis, psoriasis, [illegible] or infectious diseases.

Inhibition of *inflammation* or *hypersensitivity* of mucous membranes. This effect can be obtained in relation to any disease related to mucous membranes or any disease giving rise to such symptoms of the mucous membranes [illegible].

Suppression of IgE mediated allergic reactions.

Suppression of autoimmune reactions.
Reduction of pain.

Accordingly, the present invention provides a pharmaceutical composition or a dietary supplement comprising:

1) an extract or concentrate of *Butyrospermum* *parkii* containing at least 5% (w/w) of a Butyrospermum triterpene fraction comprising:

- at least 2% (w/w) lupeol
- at least 2% (w/w) [illegible]

In addition provides a pharmaceutical composition comprising:

a pharmaceutical [illegible] dietary supplement comprising:

i) an extract or concentrate of *Butyrospermum* *parkii* containing at least 5% (w/w) of a Butyrospermum triterpene fraction comprising:

- 10-40% (w/w) α-amyrin [illegible] - optionally 1-30...may be in the form of free alcohol [illegible] thereof, especially cinnamic acid, acetic acid or fatty [illegible]

The extract or concentrate of *Butyrospermum* *parkii* may be derived from any part of the plant, the fruit (nut), leaves, stem, bark or root. Preferably the extract or concentrate of...

...the fruit. Furthermore, the extract or concentrate of the invention may be derived from the [illegible] fat (butter) derived from the fruit of *Butyrospermum* *parkii* by extraction or fractionation, e.g. comprising [illegible]. Preferably, the triterpene alcohols [illegible] are derived from the unsaponifiable [illegible] of fat from *Butyrospermum* *parkii*.

Extracts or concentrates according to the invention can i.a. be obtained by extraction or distillation (e.g. hydro, steam or vacuum distillation) of fresh or dried *Butyrospermum* *parkii* or parts thereof, preferably the nut. Extraction may be performed with a number of different organic solvents. The extraction may be performed hot or cold...

...of extraction [illegible]

By changing the composition of the applied solvent, the extraction can be made more selective towards certain constituents of *Butyrospermum* *parkii* thus enhancing or reducing the amounts thereof in the finished extract or concentrate.
After extraction, [illegible] any type of distillation, can be employed to remove undesirable constituents of the extract. Hereby [illegible] of *Butyrospermum* *parkii* can be avoided or concentrated in the finished extract. Thus the content of any component can be [illegible] to obtain a composition according to the...

...The above mentioned pharmacological actions provide part of the rationale for the following therapeutic applications of a composition comprising an extract or concentrate of *Butyrospermum* *parkii* as described above and, optionally, a pharmaceutically acceptable carrier for systemic administration.

A method for the treatment or prevention of *hypersensitivity* disease or *inflammation* characterised by the administration of the above mentioned compositions. The therapeutic action may be relevant to all known diseases associated with hypersensitivity* reactions or *inflammation*. Autoimmune disorders and IgE mediated *allergic* conditions are described below in more detail. Besides these specific therapeutic areas, the action of the above mentioned compositions is relevant to all known conditions associated with hypersensitivity* reaction, and the following are not limiting with respect to this: infections (viral, bacterial, fungal, parasitic, etc.), cold and flu, contact dermatitis, insect bites, allergic vasculitis, postoperative reactions, transplantation rejection (graft-versus-host disease), etc. A method for the treatment or prevention of autoimmune disorders characterised by the administration mentioned compositions. The applicant puts forward the hypothesis that the therapeutic action is due to the immuno modulating and suppressing effect on hypersensitivity* reactions of the above mentioned composition. The therapeutic action may be relevant to all known autoimmune disorders and the following examples are not limiting with respect to this: Autoimmune hepatitis, Primary biliary cirrhosis, Primary sclerosing cholangitis, Autoimmune hemolytic anemias, Grave's disease, Myasthenia gravis, Type I Diabetes Mellitus, *Inflammatory* myopathies, Multiple sclerosis, Hashimoto's thyroiditis, Autoimmune adrenalitis, Crohn's disease, Ulcerative colitis, Glomerulonephritis, Progressive systemic sclerosis, Sjögren's Disease, Lupus Erythematosus.

...Rheumatoid Arthritis, Juvenile Arthritis, Mixed Connective Tissue Disease, Psoriasis, Mycosis fungoid, Dermatitis Herpetiformis, etc. A method for the treatment or prevention of an IgE mediated *allergic* reaction or condition characterised by the administration of the above mentioned compositions. The applicant puts forward the hypothesis that the therapeutic action is due to the immuno suppressing effect on *hypersensitivity* reactions of the above mentioned compositions. The therapeutic action may be relevant to all known IgE mediated *allergic* reactions and conditions, and the following examples are not limiting with respect to this: asthma, eczema (e.g. atopic dermatitis), urticaria, *allergic* rhinitis, conjunctivitis. A method for the treatment or prevention of any condition associated with pain characterised by the administration of the above mentioned compositions. The applicant puts forward the hypothesis that the therapeutic action is related to immunomodulating and suppressing effect on *hypersensitivity* reactions.

According to the above mentioned compositions the treatment or prevention is suitable for the treatment or prevention of diseases caused by *inflammation* of various tissues, e.g. *inflammation* of the prostate, in particular prostatitis.

"Prostatitis" is defined as *inflammatory* conditions affecting the prostate, including acute bacterial infections with specific bacteria and, more commonly, chronic diseases with signs and symptoms of prostatic *inflammation* where no specific organism can be detected. Accordingly, the compositions of the invention may also be employed for the management of benign prostatic hyperplasia.

...for topical use may be prepared with addition of an extract of Calendula officinale. This is illustrated in example 3, where the topical anti *inflammatory* pharmaceutical composition containing 0.1% Calendula officinale extract and 20% Butyrospermum-triterpene fraction is superior to a topical pharmaceutical composition containing therapeutic applications of a pharmaceutical composition for topical application according to the invention as described above.

A method for the treatment or prevention of *inflammation* or *hypersensitivity* of the skin or mucous membranes of a mammal, characterised by administering a pharmaceutical com position according to the invention to said mammal. The therapeutic action may be rele vant to all known diseases associated with *hypersensitivity* reactions or *inflammation*, in cluding autoimmune disorders and IgE mediated *allergic* condition. The action of the above mentioned pharmaceutical compositions according to the invention is relevant to all known conditions and diseases of which the pathogenesis is connected with *hypersensitivity* reaction, and the following examples are given by way of illustration with respect to this.- infections (viral, bacterial, fungal, parasitic, etc.), cold and flu, contact dermatitis, psoriasis, atopic dermatitis, psoriatic arthritis, postoperative reactions, transplantation reactions (graft-versus-host disease), asthma, eczema (e.g. [illegible] dermatitis), allergic* rhinitis, anaphylaxis, [illegible] hepatitis, [illegible] cirrhosis, Primary sclerosing cholangitis, Autoimmune hemolytic anemias, Grave's disease, Myasthenia gravis, Type I Diabetes Mellitus, *Inflammatory* myopathies, Multiple sclerosis, Hashimoto's thyreoiditis, Autoimmune adrenalitis, Crohn's Disease, Ulcerative Colitis, Glomerulonephritis, Progressive Systemic Sclerosis (Scleroderma), Sjögren's Dis ease, Lupus Erythematosus, Primary [illegible] used for the preparation of a pharmaceutically active composition as described above for systemic administration characterised by ob taining an extract or a concentrate of *Butyrospermum* *parkii* said extract or concentrate comprising at least one triterpene alcohol selected from the group consisting of buty rospermol, lupeol, parkeol, [illegible], cammaradienol, 24-methylene dammarenol administration.

EXAMPLES

Example 1

Summary of the study

BPC, a concentrate of Butyrospermum parkii according to the invention, was evaluated for [illegible] inflammatory* activity in BALB/c mouse arthritis induced by [illegible] ticne antibody (mAb) and lipopolysaccharide. The [illegible] ne was administered orally once daily for 3...

...14 and 17.

Test substance
A composition according to the invention was prepared by fractionation of shea butter and subsequent [illegible] obtained concentrate of *Butyrospermum parkii* [illegible] applied concentrate of Butyrospermum [illegible] ned 26% of a Butyros permum -[illegible] ects of compositions according [illegible] or a known composition containi[illegible] polished a[illegible]ay of topical anti-*inflammatory* [illegible] in mouse ear inflammation in the mouse.

Methods
Four compositions according to the invention, a control composition containing shea butter [illegible]
...control composition was [illegible] without any further addition. The four pharmaceutical [illegible] of the invention were prepared by the addition of [illegible] permum* *parkii* (obtained by fractionation of [illegible] corresponding to a content of Butyrospermum-[illegible] 20%.

The control [illegible] triterpenes.

The assay was performed according to [illegible] (Euro. J. Pharmacol. (1987)142:197).

Ear *inflammation* was induced by topical application of phorbol ester. Groups of five BALB/c mice were pre-treated 30 minutes before phorbol ester application and 15...

...according to the invention containing at least 5% Butyrospermum-triterpenes possessed marked anti-inflammatory effects, while an ordinary shea butter formulation has no anti *inflammatory* effect.

Thus the study clearly indicates that a pharmaceutical composition according to the invention is pharmacologically far superior to an ordinary Shea Butter formulation

Example...

...20% Butyrospermum triterpenes and 0, ... end ... extract were compared in a well established assay of topical ... *inflammatory* activity, phorbol ester induced *inflammation* in the mouse.

Methods
Two compositions according to the invention and a negative control composition were prepared based on the following creme base:

Hydrogenated rapeseed...

...control composition was prepared without any further addition. The two pharmaceutical compositions according to the invention were prepared by the addition of a concentrate of *Butyrospermum* *parkii* (obtained by fractionation of the ... butter) corresponding to a content of Butyrospermum-triterpenes ... Furthermore one of them was...

...1 % Calendula ... (prepared by supercritical C02 extraction...

The assay was performed according to Chang et al (Euro. J. Pharmacol. (1987)142:197).

Ear *inflammation* was induced by topical application of phorbol ester. Groups of five BALB/c mice were pre-treated 30 minutes before phorbol ester application and ... 4 hours.

Test substance
A composition according to the invention was prepared by fractionation of shea butter and subsequent ... the obtained concentrate of *Butyrospermum* *parkii* ... The applied concentrate of Butyrospermum (termed BPC ... following ... obtained 33% of a Butyrospermum ...

...and placebo ... clinical study is performed in patients suffering ... to test the safety and efficacy of a concentrate of *Butyrospermum* *parkii* according to the invention.

Test substance
A composition according to the invention is prepared by fractionation of shea butter and subsequent ... the obtained concentrate of *Butyrospermum* *parkii* ... capsules each containing 750 mg of the concentrate ... of Butyrospermum (termed BPC in the following ... and placebo controlled phase II clinical study is performed ... suffering from psoriasis to test the safety and efficacy of *Butyrospermum* *parkii* according to the invention.

A similar study in ... suffering from atopic dermatitis using the same pharmaceutical composition according to the invention is under preparation.

Test substance

A composition according to the invention is prepared by fractionation of shea butter and subsequently formulating the obtained concentrate of *Butyrospermum* *parkii* in a standard cream base containing 40% of the concentrate. The components of the cream base are:

Water, PEG-6 stear... Glycol Stearate, PEG-32...

Claim
CLAIMS

1. A pharmaceutical comp... dietary supplement comprising:

i) an extract or con... parkii* containing at least 5% (w... act on comprising:

- at leas... (w/w)...
- at least ...% (w/w)...

...fatty acid esters; and ii) optionally a pharmaceutically acceptable carrier.

2. A pharmaceutical compositi... a dietary supplement comprising:

i) an extract or concentrate ... rospermum* *parkii* containing at least 5% (w/w) of a Butyrospermum ... triterpene fraction comprising:

- optionally 2-30% ge... tirad enol, 24-methylene-dammarenol and/or parkeol, wherein ...

...ii) optionally a pharmac... t... carrier.

3. A pharmaceutical ... y supplement according to claim 1 or 2, ... the extract or concentrate of *Butyrospermum* *parkii* further comprises a ste... fraction comprising at least one sterol selected from the group consisting of stigmasterol, avasterol, 24-methyl-cholest-7-enol, campesterol...

...preceding claims, wherein ... Butyrospermum-triterpene fraction optionally together with ... fraction comprises up to 100% (w/w) of the extract or concentrate of Butyrospermum* *parkii*.

5. A pharmaceu... supplement according to any of claims 3 or 4, ... the Butyrospermum-triterpene fraction and the...

...of a composition ..., claims 1 to 9 for the preparation of a medicament or ... for the suppression of *hypersensitivity* ... mmation in a mammal.

12. The ... for the preparation of a medica... prevention of *inflammation* or *hypersensitivity* ... membranes in a mammal.

13. The use accordi... 12 for the preparation of a medicament or a diet... or the treatment or prevention of autoimmune disease and/... inflammatory* disease in a mammal.

14. The use ... preparation of a medicament or a dietary supp...

...a dietary supp... prevention of prostatitis and/or be nign prosta...

17. A method for the ... of *hypersensitivity* or *inflammation* ... by administering a composition according to any of ... to a mammal.

18. A method for ... or prevention of *inflammation* or *hypersensitivity* of the skin or mucous membranes of a mammal,

characterised by administering a composition according to any of claims 1 to 9 to said mammal.

19. A method for the treatment or prevention of an autoimmune disorder and/or a chronic inflammatory disorder in a mammal, characterised by administering a mixture according to any of claims 1 to 9 to said mammal.

20. A method for the...

...A method for the preparation of a composition according to any of claims 1 to 9, characterised by obtaining an extract or a concentrate of *Butyrospermum* *parkii* extract or concentrate containing at least 5% (w/w) of a Butyrospermum parkii extract comprising:

- at least 1...
- at least 2...

...esters thereof, especially cinnamic acid, acetic acid or fatty acid esters; and 24. A method according to claim 22, wherein the extract or concentrate of *Butyrospermum parkii* further comprises a sterol fraction comprising... especially cinnamic acid, acetic acid or fatty acid esters.

25. A method according to claim 22 or 23, wherein said extract or concentrate of *Butyrospermum parkii* is further mixed with a pharmaceutically acceptable carrier.

2/6,K/14 (Item 5 from file: 349)
DIALOG(R)File 349: (c) 2... reserv.

00680915

COMPOSITIONS FOR USE IN COSMETICS OR DERMOPHARMACEUTICS CONTAINING A MIXTURE OF GREEN COFFEE EXTRACT AND SHEA BUTTER
COMPOSITIONS A USAGE COSMETIQUE OU DERMOPHARMACEUTIQUE CONTENANT UN MELANGE D'EXTRAITS DE CAFE VERT ET DE BEURRE DE KARITE

Publication Language: French
Filing Language: French
Fulltext Available:
Detailed Description
Claims
Fulltext Word Count: ...
Publication Year: 1999

Fulltext Availability:
Detailed Description
Claims

English Abstract
...plant extract of < i> Coffea canephora< /i> or < i> Coffea canephora< /i> green coffee and the shea butter obtained from the shea tree or < i> *Butyrospermum* *parkii*< /i> shea nut, and its use in cosmetic or dermopharmaceutical compositions. The product resulting from said association is used in cosmetic or...

...medicine for healing... soothing effects, including treatment against skin... medical forms of oxygen such as, for example... skin ageing or withering, occurrence of wrinkles... ng protection of the hair, scalp, nail and mucous membranes.

French Abstract
...i> ou < i> Coffea canephora< /i> a du beurre de karite obtenu a partir de l'arbre a karite< /i> *Butyrospermum* *parkii*< /i> notamment, ainsi que son utilisation dans des compositions a usage cosmetique ou dermopharmaceutique. Le produit resultant de cette association est utilisable en tant que...

...et la recherche d'effets [illegible] cutanes, y compris contre les consequences des effets deleteres des formes radicalaires de l'oxygene comme, par exemple, l'inflammation cutanee, le vieillissement ou le dessechement premature de la peau, l'apparition des rides, ainsi que pour favoriser la protection des cheveux, du cuir chevelu...

Detailed Description

... dermopharmaceutique contenant un melange d'extraits de cafe vert et de beurre de karite Les sensations douloureuses et de gene ressenties localement lors d'episodes [illegible], sont dues a la desormais trilogie classique (Arthur [illegible] signes cardinaux suivants: erytheme, oedeme et douleur.

Les formes radicalaires de l'oxygene...

...Okuda, [illegible] 92

Le second mecanisme [illegible] activation de differents types de cellules qui secretent des molecules pro-inflammatoires*, telles que les polynucleaires neutrophiles humains, qui liberent, parmi d'autres mediateurs de l'*inflammation*, de grandes quantites de collagenase, d'elastase, et de hyaluronidase stockees dans leurs granules azurophiles (Vender (1 996) J [illegible] ed [illegible] 53 529).

A...

...les situations douloureuses [illegible]
Les polyphenols et [illegible] les acides hydroxy-cinnamiques dont l'acide chlorogenique ou [illegible] possedent des activites anti *inflammatoires* [illegible] contre ses modifications biochimiques, que cette [illegible] d'origine *allergique* ou non, (Kimura et al. [illegible] 73 17) En effet, cette classe de molecules a des [illegible] contre les effets deleteres...[illegible], [illegible] l'effet obtenu.

Le beurre de karite [illegible] obtenu, a partir de noix de l'arbre a karite ou *Butyrospermum* [illegible] selon un procede classique qui ne fait pas [illegible] l'invention.

En fonction [illegible] du cafe vert en...sans l'association.

Les effets specifiques [illegible] sur les constituants des tissus de soutient degrades [illegible] au cours de l'*inflammation* seront rapidement [illegible] trois exemples suivants.

Exemple 3 [illegible]
Une solution [illegible] en absence d'un systeme...
...extrait.

Exemple [illegible]
Les radicaux libres [illegible] naturellement presente dans les tissus.

Cette enzyme active [illegible] aux manifestations tissulaires de l'*inflammation* [illegible] molecule de soutien qu'est l'elastine.

Cette serie d'experiences [illegible] a inhiber une suspension d'elastine et...et la recherche [illegible] cutanes, y compris contre les consequences des effets [illegible] formes radicalaires de l'oxygene comme, par exemple, [illegible] cutanee, le vieillissement ou le dessechement premature [illegible] apparition des rides, ainsi que pour favoriser la protection [illegible] du cuir chevelu...

Claim

... vert Coffea arabica [illegible] Coffea canephora L. Pierre a du beurre de karite obtenu a partir de noix de l'arbre a karite ou *Butyrospermum*

parkii Kotschy.

2. Produit selon l caracte ise en ce que l'extrait de cafe contient des polyphenols, notamment des acides hydroxy-cinnamiques et parmi ces derniers...

...et la recherche d'effets apaisants cutanes, y compris contre les consequences des effets deleteres s formes radicalaires de l'oxygene comme, par exemple, l'inflammation cutanee, le vieillissement ou le dessechement premature de la p apparition des rides, ainsi que pour favoriser la protection du cuir chevelu...

2/6,K/15 (Item from file:
DIALOG(R)Fi s. observ.

00679815
FRACTIONATION PROCESS
PROCEDE DE FRACTIONNEMENT
Publication Language: Engli
Filing Language: English
Fulltext Availability:
Detailed Description
Claims
Fulltext Word Count: 9630
Publication Year: 1999

Fulltext Availability:
Detailed Description
Claims

Detailed Desc
... inclus

The unsaponifiable lipids of she outter are characterized by a high content of UV-abso.bing cinnamp esters and natural phytosterols claimed to impose - mm y* ffects on damaged skin. The unsaponifiable lipid eed oil are dominated by a unique high content of sterol tos ol, campesterol and...

...well as tocophe natural protection against oxidation. An un of rapeseed oil has proven to show an anti *inflammatory* irritated skin (Lod6n, M., et al., Effect of topically a surfactant-irritated skin, British Journal of Dermatolog -20...kernel oil (Elaeis guineensis, oleifera), (Cocos ucifera), babassu oil (Orbignya martiana oleifera), Borneo tallow (Shorea stenoptera), B rum* *parkii*), madhuca, mowrah bu ca lo ia), sal butter (Shorea robusta), ma s ra a), avocado oil, avocado seed oil (Persea ameri ter physical filter in a skin care formulation ca ne (the ci erpe alcohols and phytosterols, which have been e d in the a ion, have an anti-*inflammatory* action. These sub es als a stabilising effect on cell membranes, which impro the wat ding capacity of the epidermis, giving a desired mois fraction. Tocopherols in combination with phyt t known to show membrane stabilising pro improved water binding capacity of the epidermis. Sne y* roperties on surfactant damage skin is also relate s. An anti-irritant and anti-*inflammatory* effect n also be attributed to the combination of phyto rols.

EXAMPLES
In the follo fi at on xam s a fined vegetable oil...second, lower fr t tem a ore the unit of free and esterified ste s in the pdu

Example 5. Fractionation of shea butter
A bleached shea butter (Butyrospermum *parkii*) having a melting point of 34'C was first fractionated at +40C using a temperature gradient of 0.50C/minute and an acetone/oil ratio...of Tioxide Chemicals Inc., USA.

LIPEX Shea-U is a shea butter fraction prepared according to Example 5 or 6.

BIOLOGICAL TESTS
Test 1. Anti-*inflammatory* [illegible]
The aim of this study was to assess the protective effect of test products on stimulated dermal keratinocytes (NHEK) by measuring production of IL-8 production The IL-8 concentrations were normalized by protein contents and the [illegible] In basal conditions, croton oil induced an increase in IL-8 production by approximately [illegible] time. A consistent reduction...

...Canola oil fraction treated cultures and from Hydrocortisone treated cultures were assayed for the presence of IL-8 suggesting that these two products depressed the *inflammatory* response induced by croton oil. The Canola oil fraction reduced IL-8 approximately 24% at C,, C2 and C3.

Hydrocortisone reduced IL-8 [illegible].

...Shea buttersfraction at [illegible] IL-laproduction The intracellular IL-1a concentrations (pg/[illegible] values were corrected by protein contents and the anti-inflammatory activity %) was calculated. In basal conditions (untreated values) croton oil stimulated the production and intracellular accumulation of IL-1a. The intra cellular accumulation [illegible] the efficiency of the 4 tested [illegible] could be considered as equivalent and the anti-*inflammatory* effect was about 30%. As recorded for IL-8, the anti-*inflammatory* effect of Hydrocortisone was higher than that observed with Canola oil fraction. Hydrocortisone reduced IL-1a by approximately 60% at the lowest tested concentration.

In contrast to its effect on IL-1a production, Shea oil fraction reduced the *inflammatory* response induced by croton oil. If we considered the protein contents as identical, the efficiency of the 4 tested concentrations of the fraction could be considered as equivalent and the anti-*inflammatory* effect was about 25%.

Test 2. UV radiation [illegible] ed rapeseed oil in vitro The fractionated low-[illegible] of Example 1, the canola...

Claim
... fraction [illegible] shea [illegible] ingredient of a cosmetical or pharmaceutical composition, [illegible] for [illegible] skin moisturizing, [illegible] treatment [illegible] *inflammatory* properties.

2/6,K/16 (Item [illegible] from file [illegible])
DIALOG(R)File 349:(c) 20[illegible] WIPO/[illegible] All rights reserv.

00666964
SKIN LIGHTEN [illegible] MAGNESIUM ASCORBYL PHOSPHATE AND UNINONTAN-U4< sup> [illegible] FORMULATION OF CUCUMBER EXTRACT AND LEMON EXTRA...
COMPOSITION ECLAIRCISSANTE [illegible] TENANT DU PHOSPHATE D'ASCORBYLE DE MAGNESIUM ET L'EXTRAIT [illegible] U4< sup> TM < /sup> (FORMULATION D'EXTRAIT DE CONCOMBRE ET L'EXTRAIT DE CITRON)
Publication Language [illegible]
Filing Language : English
Fulltext Availability:
Detailed Description
Claims
Fulltext Word Count : [illegible]

Publication Year: 1999

Fulltext Availability:
Detailed Description

Detailed Description
... lead to unwanted freckles or dark spots on the skin, such as senile lentigo, liver spots, melasma, brown or age spots, vitiligo, sunburn pigmentation, post-*inflammatory* hyperpigmentation due to abrasion, burns, wounds or dermatit[illegible], phy[illegible]tic reaction and other similar small, fixed pigmented lesions. [illegible] is o[illegible] desirable to lighten these areas... tinctorius) oil, sage [illegible] extract, sage (salvia officinalis) oil, [illegible] (santalum album) oil, serine, serum [illegible] shea butter (*butyrosr[illegible]), [illegible]hicone, sodium borate, sodium [illegible], sodium chloride, sodium chondroitin sulfate, sodium [illegible]rcaptoacetate, sodium DNA, sodium hexametaphosphate, sodium hyaluronate, [illegible]hlorite, retinol, retinyl palmitate, RNA, rosemary (rosmarinus officinalis) extract, royal jelly, safflower (carthamus tinctorius) oil, sage (salvia officinalis) extract, sesame (sesamum indicum) [illegible] shea butter (*butyrospermum* *parkii*), silica, simethicone, sodium [illegible]orate, sodium cetearyl sulfate, sodium chloride, sodium dehydroacetate, sodium hyaluronate, sodium hydroxide, sodium PCA, soluble collagen, sorbic acid, sorbitan oleate, sorbitan sesquioleate...sage (salvia officinalis) extract, sage (salvia officinalis) oil, salicylic acid, sandalwood (santalum album) oil, serine, serum albumin, sesame [illegible], sesame (sesamum indicum) oil, shea butter (*butyrospermum* *parkii*), silica, simethicone, sodium benzoate, sodium bicarbonate, sodium [illegible], sodium [illegible]orate, sodium C12-15 alkyl sulfate, sodium [illegible], sodium chondroitin sulfate, sodium [illegible]

2/6,K/17 [illegible]
DIALOG(R)File 349: [illegible] IP[illegible]or[illegible] All rights reserv.

00605722 **Image available**
COMPOSITIONS FOR COSMETIC [illegible]
COMPOSITIONS POUR APPLICAT[illegible]ION COSMETIQUE
Publication Language: [illegible]lish
Filing Language: Eng[illegible]
Fulltext Availability:
Detailed Descriptio[illegible]
Claims
Fulltext Word Count: 34[illegible]
Publication Year: 199[illegible]

Fulltext Ava[illegible]
Detailed
Claims

Detailed Description
... Such additional [illegible]ts ma[illegible]e, b[illegible] are not limited to, preservatives, abra[illegible], [illegible], antiacne agents, anti-aging agents, antibacterials, anticaking, [illegible]es agents, anticellulites, antidandruff, anti-fungal, [illegible]ammatories*, anti-irritants, antimicrobials, antioxidant[illegible]sp[illegible]ants, antiseptics, antistatic agents, astringents, b[illegible]ers, [illegible], additional carriers, chelators, cell stimulants, cleansing age[illegible] SUBSTITUTE SHEET (RULE 26) conditioners, deodor[illegible], [illegible] acetylcysteine, and retinoids, such as retinoic acid and its [illegible] may be used.

By way of exa[illegible]mple only [illegible] [illegible]-inflammation*, non-steroidal anti *inflammatory agent[illegible]s[illegible] may be used, such as propionic acid derivatives, [illegible]etic acid, fen[illegible]ac derivatives, biphenylcarboxylic acid derivat[illegible], [illegible]foams, including but [illegible] limited to aspirin... unpleasant odors An[illegible]dandruff: [illegible]ards or eliminates dandruff Depilatory: removes hai[illegible] chemical / Antifoam: suppresses foam during

mixing Detergent: a su[illegible]e-active agent (surfactant) that Anti-*inflammatory*: re[illegible] suppresses, cleans by emulsifying oils and suspends counteracts [illegible] particulate soil Anti-irritant: reduces, suppresses or[illegible] Disinfectant: destroys pathogenic irritation microorganis[illegible] Microbial: destroys...acid Black walnut (Juglans nigra) extract [illegible] (Echinacea angustifolia) extract Anticaking Orange [illegible] extract [illegible] starch octenylsuccinate Pfaffia paniculata. [illegible] stearate Distarch phosphate Anti-*inflammatory* Hydrated si[illegible] [illegible] polygalacturonic acid Kaolin Bisabolol Magnesium myris[illegible] [illegible] Black poplar (Populus nigra) extract Polyethylene [illegible] [illegible] Silica silylate Butcherbroom ...

...collagen amin[illegible] [illegible] amino acids Passion flower (Passiflor[illegible] [illegible] [illegible] officinalis) extract [illegible] [illegible] Antimicrobial Shea butter (*Butyrospermum* *parkii*) [illegible] Sodium carboxymethyl beta-glucan Benzoic acid [illegible] (Glycine soja) protein Benzyl alcohol Stearyl glycyrrhetinate B[illegible] Stenocalyx micalii extract 2-Bromo-2-nitropropane-1,3-diol Salmon (Salmo) egg extract PPG-5-laureth-5 Sesame (Sesamum indicum) oil PPG-5 butyl ether Shark liver oil PPG-5 lanolin[illegible] Shea butter (*Butyrospermum* *parkii*) PPG-5 pentaerythrityl ether Shea butter (*Butyrospermum* *parkii*) extract PPG-7-buteth-10 Shea butter, [illegible] Shorea stenoptera butter PPG-8/SMDI copolymer Silybum [illegible] ethyl ester PPG-9 Sitostearyl acetate PPG-9...75 hydrolyzed [illegible] stannate Quaternium-79 hydrolyzed silk Scalp stimulant - Bir[illegible] leaf extract Rice (Oryza sativa) starch Sebosta[illegible] [illegible] saccharina extract Shea butter (*Butyrospermum* *parkii*) [illegible] [illegible] - Hydrolyzed wheat protein Shorea s[illegible] [illegible] silcxane Silica Skin barrier lipid [illegible] [illegible] S. MEA-stearate... Carthamus [illegible] [illegible] [illegible] portate, S. protein complex Succ[illegible] [illegible] [illegible] Serum albumin T[illegible] [illegible] (Se[illegible]um indicum) oil Trimethainkne Shea butter (*Butyrospermum* *parkii*) Shea butter (*Butyrospermum* *parkii*) extract Oil absorber [illegible] [illegible] butter Hydrated silica Silk amino acids Polymethyl [illegible] [illegible] carboxymethyl beta-glucan Silicon dioxide hydrate Sodium [illegible] [illegible] sulfate Walnut (Juglans...

Claim

... cosmetic age[illegible] [illegible] [illegible] fections or disorders of the skin is selected [illegible] [illegible] of acidulents, antiacne agents, anti-aging age[illegible] [illegible] [illegible] tories*, anti irritants, antioxidants, depi[illegible] [illegible] [illegible] disinfectants, emollients, exfoliants, humectan[illegible] [illegible] [illegible], skin conditioners, skin protectants, sk[illegible] [illegible] [illegible] ting agents, sunscreening agents, and [illegible] [illegible] va[illegible] [illegible] [illegible] acidulents, anhacne agents, an[illegible] [illegible] [illegible], anticaries agents, anticellul[illegible] [illegible] [illegible] [illegible] mmatories*, anti irritant[illegible] [illegible] [illegible] [illegible] ng [illegible] antiperspirants, antisep[illegible] [illegible] [illegible] [illegible], [illegible], additional carriers, chelators, [illegible] [illegible] [illegible] [illegible] gents, conditioners, deodorants, depilatories, deterge[illegible] [illegible] [illegible], emollients, emulsifiers...

2/6,K/18 (I[illegible]m 9 f[illegible] file [illegible]
DIALOG(R)File 349[illegible] [illegible] [illegible] All rts. reserv.

00604811 [illegible]
COMPOSITIONS FOR C[illegible]
COMPOSITIONS UTILI[illegible]
Publication Language: [illegible]
Filing Language: [illegible]
Fulltext Availab[illegible]
Detailed Descrip[illegible]
Claims
Fulltext Wor[illegible]
Publicatio[illegible]

Fulltext Availability:
Detailed Description
Claims

Detailed Description
... Such additional components include but are not limited to, preservatives, abrasives, ... anti-acne agents, anti-aging agents, antibacterials, antic...king ... agents, anticellulites, antidandruff, antifu... ... ...mectries*, anti-irritants, antimicrobials, ant... ... ...ns, antiperspirants, antiseptics, antistatic agents, ... additional carriers, chelators, cell ... ...s, conditioners, deodorants, dipilatories, ...retinoids, such as retinoic ... ...e

By way of example only, ...lamination, non steroidal anti *inflammatory* agents (NSAID...) may be used. Such as propionic acid derivatives. acetic acid. fenamic acid derivatives, biphenylcarboxylic acid derivatives, oxicams including but not limited to aspirin...quality and quantity of lather ... ...Antifoam: suppresses foam during ...ntixing Foamer: a surfactant ...gent (surfactarit) that produces foam: an emulsion of ... Anti-*inflamma...y* reduces. suppresses. counteracts *inflammation* ... ...Astringent reduces. suppresses or prevents irritat... Foam... ...see Foam booster Antimicrobial: destroys. inhibits ...growth of Fungicide: inhibits... Passimi flower (Pas... ... ...tract Hexamidine diisethionate Antio... ... ...e imperialis extract Hinokitiol Cetylamine hyd...fluor... ... ...sulfate (Lonicera caprifolium) ex... ... ...butyrospermum* *parkii*) lichen (Usnea ... ...fluoride ... ...m carboxymethyt beta-gluca... Myrist... ...chloride ...ethyl propylenedi...amine S... ...protein ...ylene glycol dihydrofluoride ... ...glycol chelate Phenethyl...indicum) oil Polyglyceryl-2 dii... ... ...diisostearate PPG-12-PEG-65 lanolin oil Shark liver oil ... ...diisostearate PPG-12/SMDI Copolymer Shea butter (*Butyro...permum* ... ...Polyglyceryl-3 diisostearate. P. oleate PPG-14 butyl ether ... ...(*Butyrospermum* *parkii*) extract Polyglyceryl-3 st... ... ...ether. P. stearyl ether Shea butter. ethoxylated ... ...PPG ...stearyl ether benzoate Shorea stenoptera ... ...extract Ricc peptide PEG-3 lauramine ... ...officinalis) oil Sericin PPG-15 stearyl ether ... ...extract Shea butter (*Butyrospermum* *parkii*) PEG-7000 ... ...extract Shellac Sodium cocoamphoacetate ... ...extract Sodium C12-15 pareth-7 sulfonate Sod... ... ...Sod... hyaluronate Sodium... oleate custo... ... ...PPG40 bull ether Quatemium-...

Quatemium ...
Rice (Orya... ... R...
Shea butter (*Butyro... ... ...extract CHEMICAL COMPANY Shorea stenoptera butter ... ...glewood. NJ 07, 631 Silica Stearamide MEA. S. MEA-st... ... ...e: 2...-569-8934 * Fax...arnino acids Lactamide DGA, L...MEA Soy... ... ...ajen Octic acid Sesame (Sesamum indicum) oil C... ... ...dilaurate Lactobacillus/whey ferment Shea b... ... ...*parkii*) Copper aspartate. C. protein comple... ... ...te Shea butter (*Butyrospermum* *parkii*) extrac... ... ...methylsilanol elastinate Shorea stenopter... ... ...(Gossypium ... oil Lanolin alcohol Silk amino acids Cra... ... ...tri... ...cetyl PCA...

Claim
... cosmetic agent... ... ...tion or disorders of the skin is sele... ... ...consisting of acidulents, anhacne agents, anti-aging agents, ...matori... anti irritants, antioxidants, depilator... ... ...fectant, emollients, exfoliants, humectants, lubri...nt, moi...zers, skin conditioners, skin

This study (Konning) has b

...oil free formulations, it has a good spreadability and quick rub-in properties.

Following is a list of Shea butter regulatory agreements:

	Shea butter
INCI	(*Butyrospermum* *parkii*)
CAS no.	9 80 - - 8
Europe ELINCS no.	2 - 7
Japan CLS no.	523 10

DEFINING (
Shea butte
?